Coronary Microvascular Dysfunction in the Spotlight at EuroPCR 2026

June 15, 2026

EuroPCR 2026 | VahatiCor Symposium Recap

Micro is Huge.

This year at EuroPCR, physicians and industry filled the symposium room yet again, to continue the important  conversation around addressing Coronary Microvascular Dysfunction.

The smallest vessels matter. Micro is Huge.

The internationally recognized faculty shared early findings from SERRA-I, the early feasibility study of the A-FLUX Reducer System in patients with symptomatic CMD and shared the outlook to a pivotal SERRA-II trial. As during the previous edition, there was dynamic interaction of the faculty with the audience. It included a congratulatory comment from Prof. Shmuel Banai, recognized as a founding voice in coronary sinus reducer therapy.

Thank you to our speakers, our moderators, and the audience who showed up for the patients we’re working for.

Faculty Grid

Dr. Bruce Samuels

Cedars-Sinai Medical Center

Prof. Tommaso Gori

University Medical Center Mainz

Dr. Carlos Collet

Cardiovascular Research Foundation, New York

Dr. Francesco Giannini

Policlinico San Marco, Bergamo / IRCCS Galeazzi Sant’Ambrogio, Milan

Dr. Tim van de Hoef

University Medical Center Utrecht

Prof. Alexandra Lansky

Yale University School of Medicine

Dr. Samit Shah

Yale University School of Medicine

Didn’t catch it live? You can watch the full session here:

Standout takeaway from our speakers, in their own words:

Dr. Carlos Collet
Cardiovascular Research Foundation, New York
On diagnosing CMD and the case for routine testing

“CMD is coming, one out of two (patients). Don’t forget that number.”

“If you have microvascular dysfunction, you have five times more risk to die.”

“We have been very successful over the last five years to increase the awareness of this disease called CMD. But now we are in a time that we have to move from awareness to routine implementation of the diagnostic test to serve this population.”
“If the patient comes to the lab, you’re already with the catheter in the coronary, and you don’t find epicardial disease, and the patient has angina, you have to have a diagnosis. That’s the opportunity.”
Dr. Francesco Giannini
Policlinico San Marco / IRCCS Galeazzi Sant’Ambrogio
On the A-FLUX procedure and coronary sinus anatomy

“The A-FLUX device is a next-generation coronary sinus reducer designed to provide flow reduction and symptoms relief.”

“Based on our initial experience, counting the compassionate use cases but also the part of the early feasibility study, it appears to be safe, simple, and effective.”
Dr. Tim van de Hoef
University Medical Center Utrecht
On the SERRA-I experience and what the data is showing
“Patients enrolled in SERRA-I have a very high disease burden in spite of guideline-directed medical therapy.”
“Interventions at the level of the coronary sinus are really safe procedures, safer than the coronary arteries probably.”
“The initial data supports the feasibility of combining a diagnostic assessment and immediately performing the therapeutic procedure by implanting a coronary sinus reducer at that stage.”

Prof. Shmuel Banai

Tel Aviv Medical Center

A nod from Pr. Banai from the audience

The session closed with a congratulatory comment from Prof. Shmuel Banai, recognized across interventional cardiology as a pioneer and founding voice in coronary sinus reducer therapy.

Prof. Alexandra Lansky
Yale University School of Medicine
On the unmet need and the path forward
“This is clearly an incredibly unmet need.”
“These are profoundly symptomatic patients.”
“This device has the potential to fundamentally change how we approach CMD patients.”
“These centers are going to have the opportunity to define the future standard of care for this patient population.”
Dr. Bruce Samuels
Cedars-Sinai Medical Center
On diagnosis as a form of care

“Sometimes even having a diagnosis without therapy is very therapeutic.”

Moments from a packed house, global panel, and energized discussion.

The views and opinions expressed by the presenter are their own and do not necessarily reflect those of VahatiCor Inc.

The device is an investigational product, limited by applicable laws and regulations to investigational use only. It is not approved for sale or commercial distribution.